POCTA submits request that CMS update the medically unlikely edit (MUE) from one (1) to three (3) for CPT code – 87494 – for multiplex amplified probe tests that detect and report individual results for chlamydia and gonorrhea.
POCTA submits a request that CMS establish a medically unlikely edit (MUE) of three (3) for new CPT code – 87494 – for multiplex amplified probe tests that detect and report individual results for chlamydia and gonorrhea.
POCTA writes follow-up letter to Centene requesting revisions to its Physician’s Office Lab Testing Policy to add certain codes to its list of covered services when performed by a physician office laboratory.
POCTA joins more than 30 organizations in letter of support for the RESULTS Act.
POCTA sent a letter to CMS requesting the agency update the NCCI manual to reflect coding changes recently approved by the CPT Editorial Panel on HPV testing.
POCTA issues a press release welcoming SEKISUI Diagnostics as its newest member.
POCTA submitted comments supporting the preliminary determinations for six CPT codes related to infectious agents and traumatic brain injury.
POCTA submitted comments supporting the finalized CLFS payment rates for five tests for neurodegenerative disease. These tests saw an increase in payment from the proposed rates.
Read POCTA’s position paper on RESULTS, which includes background and summary information on the legislation.
POCTA submits comment letter for the CY2026 Medicare Physician Fee Schedule (MPFS) proposed rule.
POCTA submits comment letter for the CY2026 Medicare Hospital Outpatient Prospective Payment System (OPPS) proposed rule.
POCTA leads stakeholder letter to Horizon BCBS on coverage for POC respiratory pathogen testing.
POCTA submitted comments urging CMS to increase the proposed CLFS payment rates for five tests for neurodegenerative disease (82233, 82234, 83884, 84393, 84394).
POCTA responds to OMB RFI on deregulation effort, including highlighting changes to the QW modifier and revisions to the NCCI Policy Manuals.
POCTA joined Urgent Care Testing Association in sending a letter to Oklahoma Health Care Authority raising concerns related to restrictions to point of care molecular testing.
POCTA and partner organizations UCA and IDSA write letter to Oklahoma Health Care Authority requesting changes to significant restrictions on point of care molecular testing for certain respiratory diseases for symptomatic beneficiaries.
POCTA issues a press release welcoming Infectious Diseases Society of America (IDSA) as Partner. The Partner program was launched to build stronger ties with key stakeholder organizations to more effectively promote medically appropriate and cost-effective point of care testing.
POCTA, UCA, and AdvaMed write letter to Centene requesting revisions to its Physician’s Office Lab Testing Policy to add certain codes to its list of covered services when performed by a physician office laboratory.
POCTA responds to the request for stakeholder input regarding the next steps for the Cures 2.0 Act (“CURES 2.0”).
POCTA issues a press release welcoming Urgent Care Association (UCA) as Partner. The Partner program was launched to build stronger ties with key stakeholder organizations to more effectively promote medically appropriate and cost-effective point of care testing.
POCTA issues a press release welcoming Urgent Care Association (UCA) as Partner. The Partner program was launched to build stronger ties with key stakeholder organizations to more effectively promote medically appropriate and cost-effective point of care testing.
POCTA issues a press release welcoming Association for Diagnostics & Laboratory Medicine (ADLM) as Partner. The Partner program was launched to build stronger ties with key stakeholder organizations to more effectively promote medically appropriate and cost-effective point of care testing.
See changes to the collection and reporting periods as a result of recent legislative changes included in the Consolidated Appropriation Act, updated November 2023.
POCTA issues a press release welcoming AdvaMed as Partner. The Partner program was launched to build stronger ties with key stakeholder organizations to more effectively promote medically appropriate and cost-effective point of care testing.
POCTA leads letter to the Centers for Medicare and Medicaid Services (CMS) encourage the agency to instruct State Medicaid programs to recognize and process claims submitted with Proprietary Laboratory Analysis (“PLA”) codes established by the American Medical Association’s Current Procedural Terminology (“CPT”) Editorial Panel.
POCTA writes letter to Centers for Medicare and Medicaid Services (CMS) requesting certain improvements to the Transitional Coverage for Emerging Technologies (TCET) pathway.
POCTA writes letter of support to House Energy and Commerce Committee leadership for the diagnostic testing plan requirements included as part of the Pandemic All Hazards Preparedness Act (HR 4421).
Thirty-seven consumer and patient advocacy groups voiced support for SALSA. These groups sent a letter to congressional leadership urging Congress to take action to enact SALSA this year and prevent a fourth round of Medicare payment cuts in January 2024. We are grateful to the National Consumers League and RetireSafe for their leadership on this issue.
Provider advocates with a strong interest in diagnostics send a letter to Speaker McCarthy, Leader Schumer, and Minority Leaders Jefferies and McConnell urging that the Saving Access to Laboratory Services Act (SALSA/ S. 1000 / H.R. 2377) be enacted this year.
POCTA issues a statement of support for the Stop Lab Cuts advocacy efforts to advance the Saving Access to Laboratory Services Act (SALSA).
POCTA issues a press release expressing support for the reintroduction of the Saving Access to Laboratory Services Act (SALSA).
Read a recent white paper from the Duke Margolis Center for Health Policy on policy steps to support practical information, availability, and affordability for innovative and convenient testing capabilities to empower Americans to protect themselves from a broad array of respiratory infections and other health risks, especially people with high risks of complications or from vulnerable communities, without substantial restrictions, extraordinary measures, or very large new government appropriations.
Read POCTA’s position paper on SALSA, which includes detailed background on the need for a legislative solution.
This Kaiser Family Foundation analysis describes how the depletion of federally-purchased supply and the potential end to the COVID-19 public health emergency may impact access to and cost of COVID-19 vaccines, treatments, and tests.
See updates on Cepheid, one of our member companies, securing the first approval for point of care test for Mpox.
POCTA, joined by QuidelOrtho, submitted comments to Centers for Medicare and Medicaid Services on the CY 2023 Clinical Laboratory Fee Schedule (CLFS) Preliminary Payment Determinations to inform the final CLFS rate determination for CPT code 87428. (CPT code 87428 describes instrumented antigen testing by immunoassay that reports separate (qualitative) results for COVID-19, influenza A, and influenza B.)
Patient advocates with a strong interest in diagnostics send a letter to Speaker Pelosi, Leader Schumer, and Minority Leaders McCarthy and McConnell urging that the Saving Access to Laboratory Services Act (SALSA/H.R. 8188/S.4449) be enacted this year.
POCTA submits a letter to Speaker Pelosi, Leader Schumer, and Minority Leaders McCarthy and McConnell explaining that the enactment of the Saving Access to Laboratory Services Act (SALSA/H.R. 8188/S.4449) is urgently needed this year, to allow laboratories to focus on providing timely, high quality clinical laboratory services for patients, continuing to innovate, and building the infrastructure necessary to protect the public health.
POCTA responds to the Centers for Medicare and Medicaid Services on the Proposed Rule entitled, “Medicare and Medicaid Programs; CY 2023 Payment Policies Under the Physician Fee Schedule and Other Changes to Part B Payment Policies; Medicare Shared Savings Program Requirements; Medicare and Medicaid Provider Enrollment Policies, Including for Skilled Nursing Facilities; Conditions of Payment for Suppliers of Durable Medicaid Equipment, Prosthetics, Orthotics, and Supplies (DMEPOS); and Implementing Requirements for Manufacturers of Certain Single-Dose Container or Single-Use Package Drugs To Provide Refunds With Respect to Discarded Amounts”.
POCTA responds to the Centers for Medicare and Medicaid Services August 1, 2022 Request for Information (RFI) regarding ways to strengthen the Medicare Advantage (MA) program.
POCTA and other stakeholders have joined together in support of the Saving Access to Laboratory Services Act (SALSA), which would result in several favorable reforms to the CLFS data collection and rate-setting processes that we expect would be specifically beneficial for point of care testing.
POCTA responds to the request for stakeholder input regarding the updated, introduced text of the Cures 2.0 Act (“CURES 2.0”).
POCTA comments on the Rule, Medicare Program; Medicare Coverage of Innovative Technology (MCIT) and Definition of “Reasonable and Necessary”.
Association Resourcesjen@stopandsayhello.com2024-04-11T15:20:49+00:00
Eric Zimmerman
Mike Ryan